Displaying 49 - 60 of 84
Metabolism, Alcohol & Toxicity
Why we need to talk about NASH

Why we need to talk about NASH

Webcasts
View
Metabolism, Alcohol & Toxicity
Hepatic consequences of metabolic dysregulation: NAFLD and NASH

Hepatic consequences of metabolic dysregulation: NAFLD and NASH

Webcasts
View
Metabolism, Alcohol & Toxicity
Looking ahead: how to identify high-risk patients

Looking ahead: how to identify high-risk patients

Webcasts
View
Metabolism, Alcohol & Toxicity
Navigating the NASH healthcare system: global insights and challenges (panel discussion and Q&A)

Navigating the NASH healthcare system: global insights and challenges (panel discussion and Q&A)

Webcasts
View
Metabolism, Alcohol & Toxicity
The NASH treatment pipeline: focus on anti-metabolic approaches

The NASH treatment pipeline: focus on anti-metabolic approaches

Webcasts
View
Metabolism, Alcohol & Toxicity
Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases

Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases

Webcasts
View
Metabolism, Alcohol & Toxicity
Q&A

Q&A

Webcasts
View
Metabolism, Alcohol & Toxicity
Introduction

Introduction

Webcasts
View
Cirrhosis & Complications
Meeting the challenge of severe thrombocytopenia with TPO-RAs

Meeting the challenge of severe thrombocytopenia with TPO-RAs

Webcasts
View
Cirrhosis & Complications
Pathways and service redesign – successfully integrating TPO-RAs into clinical practice

Pathways and service redesign – successfully integrating TPO-RAs into clinical practice

Webcasts
View
Cirrhosis & Complications
Evidence from the field and practical advantages of TPO-RAs

Evidence from the field and practical advantages of TPO-RAs

Webcasts
View
Cirrhosis & Complications
Welcome & Introduction

Welcome & Introduction

Webcasts
View
Displaying 49 - 60 of 84